Companies › BiOneCure Therapeutics
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BIO-106 anti-TROP-2 antibody-drug conjugate | TACSTD2 | Phase 1 | Advanced Cancer | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05320588 | BIO-106 | Phase 1 | Advanced Cancer | Oncology | Apr 2027 |
Sichuan Baili Pharmaceutical Gilead Sciences AstraZeneca Merck & Co. (MSD) Klus Pharma Lepu Biopharma Daiichi Sankyo Roche Sichuan Kelun-Biotech Biopharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.